Self-interacting BAX proteins permeabilize outer mitochondrial membranes to trigger apoptotic cell death. Czabotar et al. present two revealing structures of BAX dimers: one dimer has an activator BH3 helix bound into its canonical cleft, and the other dimer exposes a planar hydrophobic face potentially critical for membrane interactions.
Three structurally similar proteins, BAX, BID, and BCL-x L , interact in all possible heterodimer combinations to regulate mammalian apoptosis at mitochondria. BAX uniquely has the capacity to form higher-order oligomers on the outer mitochondrial membrane, leading to membrane permeabilization and cell death, but details of these crucial events are not known. BAX is activated by BID (after BID is cleaved to form tBID) and is inhibited by BCL-x L and other prosurvival BCL-2 family members. Both BAX and tBID engage their prosurvival partner by directly inserting their BH3-helix (a2) into a hydrophobic cleft on prosurvival proteins. Thus, BH3 mimetics are being exploited as therapeutics to kill tumor cells by inactivating prosurvival proteins. The BH3 helices of tBID and other BH3-only proteins are also thought to engage the analogous binding cleft on BAX during its activation, but these fleeting interactions have been difficult to capture, and no three-dimensional (3D) structures were previously available to support this model. Also absent are structures to explain how BAX monomers fit together as oligomers. The very act of exposing the hidden binding face of a BH3 helix to engage the cleft of a partner molecule requires complex structural rearrangements, yet nothing was known about these alternative structures or their transition states. In this issue of Cell, Czabotar and colleagues provide the first glimpse of such events, revealed by several new structures of BAX (Czabotar et al., 2013) .
Using peptides corresponding to the BH3 helix of BID, Czabotar et al. (2013) induced dimerization of purified BAX (minus its C-terminal transmembrane a helix 9, which prevents a9 from occupying the same cleft, characteristic of BAX monomers). In the resulting crystal structure, BAX is a domain-swap dimer analogous to a domain-swap dimer structure of BCL-x L (O'Neill et al., 2006) . This dimer is structurally equivalent to two monomers joined at the hip (bottom of the central helical hairpin a5-a6), except that the central helical hairpin has been splayed open into a pair of extended helices, such that the N-terminal five helices (''core'' domain) of one BAX molecule engages the C-terminal helixes a6-a8 (''latch'' domain) of the second BAX molecule in the usual way ( Figure 1A ). Although Czabotar et al. (2013) agree with the general consensus that the dimer swap may not be biological, two important revelations emerge from this structure.
In the domain-swap dimer of BAX, the BH3 peptide of BID occupies the canonical binding cleft of BAX, which is consistent with previous biochemical studies (Dewson et al., 2012) . This contrasts with the only other reported structure of BAX bound to a BH3 peptide. In that structure, the BH3 helix of BIM, another direct activator of BAX, binds to a ''trigger'' pocket located on the opposite face of BAX and not in the canonical cleft (Gavathiotis et al., 2008) . Importantly, Czabotar et al. (2013) show that side chains of BH3 peptides satisfyingly distinguish the binding specificities of two subclasses of BH3-only proteins, the direct (e.g., BID and BIM) versus indirect activators (e.g., NOXA and BAD, which bind to prosurvival proteins rather than BAX). Key amino acid substitutions convert NOXA and BAD peptides into direct activators of BAX. Furthermore, some of the critical BH3 side chains are not likely used for binding the trigger pocket. However, a key residue in BIM (L152) appears to be important for binding both the canonical cleft and to the trigger pocket of BAX (Gavathiotis et al., 2008) . Thus, it can be challenging to distinguish different binding sites, at least for BIM. It is also puzzling that the BH3 helix of BIM can induce BAX domain-swap dimers, yet BIM is noticeably absent from the resulting crystal structure.
To address a potential role for the BAX BH3 helix in BAX oligomerization, Czabotar et al. (2013) also solved a crystal structure of BAX-induced BAX dimers. In this domain-swap dimer, the canonical cleft is occupied by a BH3 peptide of BAX itself, implying that this is a key interface in the deadly BAX oligomer. Additional biochemical evidence indicates that a cleft-occluded mutant of BAX does not bind the wild-type BAX BH3 peptide until a compensatory mutation is placed in the BAX peptide. This cleft-occluded mutant could also be useful to provide the needed confirmation of specific binding by BID and BIM in the canonical cleft. Nevertheless, these studies provide important information that helps to define BH3 sequence motifs, a problem that continues to plague the field (Aouacheria et al., 2012) .
The second revelation arising from the domain-swap BAX dimer is a novel model of BAX activation. A BH3-induced cavity appears in the domain-swap dimer at the point where BAX will open to separate the C-terminal ''latch'' (helices a6-a8) from the N-terminal ''core'' domain (a2-a5). A similar cavity is not found in the BCL-x L -BIM structure, potentially explaining why BAX is more readily destabilized by invading BH3 helices. Thus, it is proposed that an invading BH3 helix liberates not just the buried BAX BH3 helix but also the entire ''core'' domain. To provide further evidence that there is an alternative outcome after unlatching BAX other than the domain-swap dimer, Czabotar et al. (2013) solved a very intriguing crystal structure of the N-terminal ''core'' domain alone (a2-a5), referred to as the ''BH3-in-groove'' structure ( Figure 1A ). This structure is a surprise. The ''core'' domain forms a novel dimer in which the BH3 (a2) of one molecule invades the second molecule in the same orientation as the monomer ( Figure 1B) . The startling feature of this ''core'' dimer is the exposure of a large roughly planar hydrophobic surface as a potential membrane-embedding surface ( Figure 1C ). To ask whether this novel structure exists in cells, they tested the predicted proximity of the two BH3 (a2) helices unique to this dimer. As predicted, a Cys residue placed at Glu69 resulted in a Cys69-Cys69 crosslinked dimer. Remarkably, 12 conserved bulky aromatic residues protrude from the hydrophobic surface formed by helices a4 and a5 ( Figure 1C ). The positions of helices a1 and a6-a8 were not determined in this structure, but it appears that both the ''trigger'' binding pocket and the canonical cleft are disrupted, which is consistent with release of activator BH3 proteins prior to BAX oligomerization ( Figure 1B) .
To test whether opening of the helical hairpin (a5-a6) is important to unlatch the ''core'' domain as proposed, Czabotar et al. (2013) tethered a5 to a6 by crosslinking, which allowed binding to BH3 peptides but abolished tBID-induced cytochrome c release and BAX dimerization. This model of BAX activation differs from that proposed for BIM-activated BAX, where the BIM BH3 displaces a1-a2 upon binding the ''trigger'' pocket, which in turn is suggested to release the tail anchor a9 from the opposite face and subsequently liberate the buried BH3 helix, making it available to interact with the next partner (Gavathiotis et al., 2010) . Whether a1 is part of the ''core'' or the ''latch'' is not definitively resolved and would depend on the flexibility of the loop separating a1 and a2. A recently reported NMR structure of BAX complexed with a peptide of vMIA, a viral apoptosis inhibitor, revealed a third distinct binding site on BAX nestled between the a3-4 and a5-6 hairpins . vMIA is a potent inhibitor of BAX-induced cell death, yet vMIA recruits BAX to mitochondria and does not prevent BAX oligomerization (Arnoult et al., 2004; Poncet et al., 2004) . One could guess that, by binding near the a5-a6 hairpin hinge, vMIA could prevent unlatching or alter membrane interactions.
This BAX ''core'' dimer structure potentially challenges previous models regarding the central helical hairpin (a5-a6), a defining characteristic of BCL-2 family members in solution structures. After insertion of the tail anchor (a9) of BAX and of other BCL-2 proteins into membranes, the helical hairpin apparently inserts into membranes to alter membrane curvature and facilitate pore formation, based on in vitro liposome studies (Basañ ez et al., 2002) (Figure 1C ). Perhaps the tilted helix a5 could project into the membrane in a manner consistent with reforming the a5-a6 hairpin or alternative structure to modulate membrane shape. This model is consistent with the ''core'' dimer representing a transition state in route to the BAX oligomer, as suggested. The final endpoint for BAX remains to be solved. Collectively, these new structures open new opportunities for the development of small molecules that either activate or suppress BAX activation to modulate cell death for therapeutic benefit. Czabotar et al. (2013) . (B) Novel ''core'' dimer structure of BAX formed by swapping the BH3 (helix 2) of one molecule into the position of the BH3 (helix 2) of the other molecule to create a relatively flat hydrophobic surface consisting of helices 4 and 5. Diagram represents a top-down view of the dimer with a membrane in the plane of the page. The locations of helices a1 and a6-a8 are inferred and are in gray to delineate. (C) Rotated view of the central a4-a5 helices, in which 12 bulky hydrophobic side chains orient toward the membrane. Helices may either directly embed into the membrane to alter membrane structure or possibly reorient to form the a5-a6 helical hairpin. Lipids in bold indicate displacement of molecules due to helix integration into the membrane, leading to changes in membrane curvature.
